Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. trimmed its holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 70.5% during the third quarter, HoldingsChannel.com reports. The firm owned 109,816 shares of the company’s stock after selling 261,861 shares during the period. Point72 Asset Management L.P.’s holdings in Werewolf Therapeutics were worth $233,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. PFM Health Sciences LP increased its stake in shares of Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares during the last quarter. Millennium Management LLC grew its holdings in Werewolf Therapeutics by 96.4% during the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after acquiring an additional 544,881 shares in the last quarter. Vanguard Group Inc. grew its holdings in Werewolf Therapeutics by 26.8% during the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after acquiring an additional 233,909 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Werewolf Therapeutics by 22.8% in the 2nd quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock worth $516,000 after purchasing an additional 39,413 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after purchasing an additional 86,800 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Werewolf Therapeutics Trading Down 7.6 %

NASDAQ HOWL opened at $1.71 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. Werewolf Therapeutics, Inc. has a one year low of $1.58 and a one year high of $8.19. The company has a 50-day simple moving average of $2.15 and a 200-day simple moving average of $2.43. The firm has a market capitalization of $76.20 million, a PE ratio of -1.12 and a beta of 0.30.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.